Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

AIDS Research and Human Retroviruses

Volumn 23, Issue 10, 2007, Pages 1237-1241

  Sánchez Conde, Matilde ^a   Palacios, Rosario ^b   Sanz, José ^c   Rodríguez Novoa, Sonia ^a   Rivas, Pablo ^a   Santos, Jesús ^b   Sola, Julio ^d   Asensi, Victor ^e   De Mendoza, Carmen ^a   Estrada, Vicente ^f   Barreiro, Pablo ^a   González Lahoz, Juan ^a   Jiménez Nacher, Inmaculada ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; MITOCHONDRIAL DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOOD INTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTICENTER STUDY; NEUROPSYCHIATRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; VIREMIA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; SPAIN; VIRAL LOAD;

EID: 35548945845     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0029     Document Type: Article

References (22)

1. Palella F, Delaney K, Moorman A, et al.: Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998;338:853-860.
2. Hammer S, Saag M, Schechter M, et al.: Treatment for adult HIV infection. JAMA 2006;296:827-840.
3. Bartlett J, De Masi R, Quinn J, Moxham C, and Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-1377.
4. Barrios A, Rendon A, Negredo E, et al.: Paradoxical CD4+ T cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005;19:569-575.
5. Barreiro P, Garcia-Benayas T, Rendon A, Rodriguez-Novoa S, and Soriano V: Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev 2004;6:234-243.
6. Damle B, Kaul S, Behr D, and Knupp C: Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol 2002;42:791-797.
7. Damle B, Yan J, Behr D, et al.: Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 2002;42:419-427.
8. Tribut O, Arvieux C, Michelet C, Chapplain J, Allain H, and Bentue-Ferrer D: Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002;24:554-562.
9. Barrios A, Rendón A, Gallego O, and Soriano V: Predictors of virological response to atazanavir in protease inhibitors experienced patients. HIV Clin Trials 2004;5:201-205.
10. De Mendoza C, de Ronde A, Smolders K, and Soriano V: Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:271-273.
11. van der Valk M, Casula M, Weverling G, et al.: Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine-or stavudine-based therapy. Antiviral Ther 2004;3:385-393.
12. Bartlett J: Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl. 1):2-10.
13. Perez-Molina JA: Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002;3:279-286.
14. Mocroft A, Phillips A, Soriano V, et al.: Reasons for stopping antiretrovirals used in an initial HAART regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Human Retroviruses 2005;21:743-752.
15. Claxton A, Cramer J, and Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
16. Maggiolo F, Migliorino M, Maserati R, et al.: Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001;6:249-253.
17. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, and Sereni D: Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in HIV-infected patients. J Infect Dis 2000;182:599-602.
18. Maggiolo F, Ripamonti D, Gregis G, et al.: Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviralnaive HIV-1-infected patients. Antiviral Ther 2003;8:339-346.
19. Santos J, Palacios R, López M, et al.: Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine and efavirenz in naive patients: The VESD Study. HIV Clin Trials 2005;6:320-328.
20. Berenguer J, Ribera E, Domingo P, et al.: Didanosine, lamivudine and efavirenz vs zidovudine, lamivudine and efavirenz, for initial treatment of HIV infection: Planned 24-week analysis of a prospective randomized non-inferiority trial, GESIDA 39-03. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 25-28 2007 (abstract 503).
21. Colebounders R, Kamya M, Laurence J, et al.: First-line antiretroviral therapy in Africa - how evidence-based are our recommendations? AIDS Rev 2005;7:148-154.
22. Stringer J, Zulu I, Levy J, et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-793.